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Abstract: Hypertension and dyslipidemia are two of the most commonly co-occurring 
cardiovascular risk factors which together cause an increase in coronary heart disease-related 
events that is more than simply additive for anticipated event rates with each condition. Data 
have shown that even relatively small reductions in both blood pressure and cholesterol levels 
can lead to large reductions in the risk for cardiovascular events. However, though there are 
robust data on the beneficial effect of concomitant reduction in these risk factors, the reality is 
that this is achieved in ,10% of patients. There is nonadherence with prescribed therapies with 
up to 50% of patients stopping their medications of their own volition for a variety of reasons. 
There is a reasonable evidence base to suggest that simplifying drug regimens and reducing 
pill burden will enhance patient adherence. The fixed-dose combination containing the antihy-
pertensive agent amlodipine besylate and the statin atorvastatin is the first combination of its 
kind, which is both efficacious and safe and could potentially improve medication compliance, 
thereby improving the outcomes in these patients.  
Keywords: amlodipine, atorvastatin, compliance, dyslipidemia, fixed-dose combination, 
hypertension
Introduction
Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide 
accounting for in excess of 930,000 deaths with an estimated direct and indirect cost of 
US$448.5 billion in 2008.1 It is a multifactorial disease, emphasizing the need to treat 
an individuals’ overall cardiovascular risk, rather than single risk factors in isolation.2
Hypertension and dyslipidemia are two of the most commonly co-occurring 
cardiovascular risk factors. In a recent study utilizing data from the third National 
Health and Nutrition Examination Survey (NHANES) it was estimated that almost 15% 
of US adults (representing approximately 30 million persons) have both hypertension 
and dyslipidemia.3 It was also shown that more than 64% of patients with hypertension 
also have dyslipidemia; conversely, approximately 47% of patients with dyslipidemia 
have hypertension.3 These two risk factors together cause an increase in coronary 
heart disease-related events that is more than simply additive for anticipated event 
rates with each disease.
Antihypertensive and lipid-lowering  
therapy and current practice
Antihypertensive and lipid-lowering medications substantially reduce the risk of CAD, 
stroke, and death in patients with cardiovascular risk factors.4–6 Data have highlighted Vascular Health and Risk Management 2009:5 378
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the importance of prompt and ‘aggressive’ control of blood 
pressure (BP) and cholesterol for patients with hypertension 
alone and for patients with additional cardiovascular risk 
factors including dyslipidemia and diabetes.5,7,8 Recent tri-
als indicate that patients with hypertension and concomitant 
multiple cardiovascular risk factors can benefit from lipid-
lowering therapy regardless of their baseline lipid levels.5
Although the importance of  treating hypertension and dys-
lipidemia is well established in treatment guidelines, the current 
rate of control is unsatisfactory. In a managed care population 
of 154,235 patients, 90% of patients in whom both hyper-
tension and dyslipidemia had been diagnosed had not met 
treatment goals for both conditions.9 Suboptimal treatment 
patterns exist despite national and international guidelines.10,11 
Moreover there is nonadherence with prescribed therapies; up 
to 50% of patients choose to stop their medications of their 
own volition for a variety of reasons.12 Factors reported to 
influence adherence include patient education and attitudes 
towards treatment, cost, complexities of treatment regimen, 
numbers of concomitant medications, and side effects.13,14
There is, therefore, a reasonable evidence to suggest 
that simplifying drug regimens and reducing pill burden 
may enhance patient adherence.13,14 A retrospective study 
of patient adherence to antihypertensive and lipid-lowering 
therapy demonstrated improvements in adherence if both 
therapies were initiated simultaneously, and if fewer other 
medications were taken concomitantly.13 The logic of 
combining multiple risk interventions for this multifactor 
disease is self evident and might be expected to enhance 
patient adherence and, therefore, improve achievement of 
treatment targets and reduce overall cardiovascular risk.
Combination therapy 
in cardiovascular disease
Polypharmacy and complex treatment regimens have been 
identified as important, modifiable risk factors for medication 
noncompliance. Poor compliance to medication regimen 
contributes to the practice-outcome gap, in which clinical 
guidelines are implemented but expected benefits are not 
realized. Fixed-dose combinations have the potential to improve 
compliance by reducing the pill burden (polypharmacy). 
A meta-analysis of nine studies which compared fixed-dose 
combinations versus free-drug components of the regimen, 
showed that fixed-dose combinations decreased the rate of 
nonadherence by 26% compared with free-drug compo-
nent regimens (Figure 1).15 A subgroup analysis of the four 
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Figure 1 Effect of fixed-dose combinations versus free-drug combination on the risk of medication nonadherence. Copyright © 2007, Elsevier. Adapted from Bangalore S, 
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studies on hypertension showed that fixed-dose combination 
decreased the risk of medication noncompliance by 24% 
compared with free-drug combination regimens.15
The fixed-dose combination containing the antihypertensive 
agent amlodipine and the statin, atorvastatin, is the first 
combination of its kind designed to treat two risk factors 
for cardiovascular disease (CVD). This article provides an 
overview of this combination.
Overview of pharmacology 
of atorvastatin and amlodipine
Amlodipine component
Amlodipine besylate, a 3rd generation dihydropyridine 
calcium channel blocker (CCB), is approved for the treat-
ment of hypertension and both vasospastic and chronic stable 
angina, alone or in combination with other agents. The pri-
mary action of amlodipine is to inhibit calcium entry through 
voltage-gated transmembrane l-type channels, thus decreas-
ing intracellular calcium concentration and inducing smooth 
muscle relaxation.16 Several important processes in athero-
sclerosis are influenced by calcium channel blockers, as they 
require calcium-dependent energy. Amlodipine also mediates 
nitric oxide release via a kinin-dependent mechanism17 and 
modulates the metabolism of collagens within the extracellular 
matrix, and thus potentially has anti-atherosclerotic-plaque-
stabilizing properties as well.18,19 It has further been proposed 
that amlodipine’s apparent anti-atherosclerotic properties 
are related to its strong lipophilicity and membrane location, 
allowing it to modulate the atherosclerotic process via both 
calcium-dependent and calcium-independent pathways.19
Atorvastatin component
Atorvastatin calcium is a synthetic lipid-lowering agent and 
is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase, which catalyzes the conversion of 
HMG-CoA to mevalonate. Inhibition of HMG-CoA reductase 
leads to upregulation of low-density lipoprotein cholesterol 
(LDL-C) receptors in the liver, mediated by activation of ste-
rol regulatory element-binding proteins resulting in enhanced 
clearance of LDL from the circulation and thus has an 
important role in preventing atherosclerosis. Atorvastatin, a 
second-generation statin, was introduced in 1996 and reduces 
LDL-C by 41%–61% in hypercholesterolemic patients.
Pharmacokinetic properties
Amlodipine/atorvastatin
The rate and extent of absorption of both amlodipine and 
atorvastatin after administration of a fixed-dose combination 
tablet has been shown to be similar to those after co-
administration of matching doses of each single agent in 
healthy volunteers in a randomized, two-way crossover 
study.20 In elderly patients, the clearance of amlodipine is 
reduced compared with in younger recipients, causing an 
increase of approximately 40%–60% in the area under the 
plasma concentration-time curve (AUC). As a result, a lower 
initial dose of amlodipine may be required in this patient 
group. The pharmacokinetics of amlodipine is not signifi-
cantly affected in patients with renal impairment. However, 
in patients with hepatic impairment, clearance is reduced 
to a similar extent as that demonstrated in elderly patients, 
and a lower initial dosage may be required. In patients with 
moderate to severe heart failure, the increase in amlodipine 
AUC was similar to that observed in elderly and patients 
with hepatic dysfunction. Atorvastatin is associated with 
higher plasma concentrations in the elderly (aged 65 years) 
than in younger patients, with a corresponding increase in 
lipid-lowering efficacy. Plasma concentrations of atorvastatin 
are markedly increased in patients with hepatic failure and 
the dosage may need to be reduced.
Rationale for single-pill amlodipine/
atorvastatin therapy
US epidemiological data have suggested that, on average, 
less than 10% of patients with concomitant hypertension and 
dyslipidemia are at target levels for both conditions.9,21 The 
large benefits that can result from simultaneous treatment of 
hypertension and dyslipidemia and the current suboptimal 
management of these conditions demonstrate that novel 
solutions are needed to treat the growing number of patients 
who have both of these important cardiovascular risk factors. 
Single-pill amlodipine/atorvastatin therapy represents such 
a solution.
The pharmacokinetic and pharmacodynamic properties 
of amlodipine and atorvastatin make them well suited for 
combination in a single pill to manage cardiovascular risk.22 
The half-lives of both agents facilitate once-daily dosing, and 
both can be administered at any time of day with or without 
food.23 Neither drug has any adverse effects on the other’s 
efficacy or tolerability.24–26
In addition a potential synergistic and dose-dependent 
increase in nitric oxide release was observed with combina-
tion treatment compared with individual components in a 
study on human vein endothelial cells taken from healthy 
volunteers.27 Moreover, combination therapy of amlodipine 
plus atorvastatin improved vascular compliance, an indi-
cator of structural and functional vascular changes, and the Vascular Health and Risk Management 2009:5 380
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beneficial effect on small arteries appeared to be more than 
additive.28,29 In normocholesterolemic obese hypertensive 
patients amlodipine plus atorvastatin reduced inflammatory 
markers and insulin resistance more than amlodipine therapy 
alone.30 Amlodipine has demonstrated some anti-atheroscle-
rotic properties, whereas the beneficial effects of atorvastatin 
on atherosclerosis, via a reduction in cholesterol levels, are 
more marked.18
Hypertension is often associated with impaired fibrino-
lysis, usually expressed by increased levels of plasminogen 
activator inhibitor type 1 (PAI-1) and decreased activity of 
tissue plasminogen activator (t-PA).31 Combination therapy 
with amlodipine and atorvastatin improved the fibrinolytic 
balance more than either single agent in hypertensive hyper-
cholesterolemic patients with insulin resistance.31
Study in transgenic ApoE * 3–Leiden mice demonstrates 
that amlodipine treatment alone did not significantly reduce 
atherosclerotic lesion development, whereas treatment with 
atorvastatin decreased lesion area substantially. The com-
bination of amlodipine and atorvastatin tended to reduce 
atherosclerosis even more, possibly especially in modest 
statin responders, which may have implications for clinical 
practice.32 Mason and colleagues have observed that the 
combination of atorvastatin and amlodipine produces a 
synergistic reduction in oxidative damage to human LDL, an 
effect not observed with other combinations of amlodipine 
and statins.33
The Regression Growth Evaluation Statin Study 
(REGRESS) trial was designed to determine the effect of 
lipid-lowering therapy with pravastatin in symptomatic 
patients with normal to moderately raised cholesterol levels. 
Although the REGRESS trial was not designed to evaluate 
combination therapy, the results suggest strongly that addi-
tion of CCBs to statin acts synergistically in retarding the 
progression of established coronary atherosclerosis.34
Key outcome trials
Amlodipine
Amlodipine effectively lowers blood pressure and reduces 
the risk of cardiovascular morbidity and mortality. The major 
outcome trials of amlodipine are listed in Table 1.
Hypertension trials
The Irbesartan Diabetic Nephropathy Trial (IDNT)35 
evaluated the effects of amlodipine or irbesartan or placebo 
in hypertensive patients with diabetic nephropathy. Although 
irbesartan was superior to amlodipine and placebo for the 
primary composite end point (doubling of the baseline serum 
creatinine concentration, the development of end-stage renal 
disease, or death from any cause), amlodipine reduced the 
time to a secondary, cardiovascular composite end point as 
effectively as irbesartan.35
In the Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT),36 more than 40,000 
high risk hypertensive patients were randomly assigned to 
receive chlorthalidone, amlodipine, lisinopril, or doxazosin. 
Amlodipine was as effective as chlorthalidone in reducing 
the primary combined endpoint of fatal coronary heart 
disease or nonfatal myocardial infarction. Moreover, it was 
more effective than lisinopril in reducing the risk of stroke. 
However, incidence of heart failure was 38% higher in 
patients assigned to amlodipine than patients assigned to 
chlorthalidone.
Valsartan Antihypertensive Long-term Use Evaluation 
(VALUE) trial was designed to test the hypothesis that, 
for the same BP control, valsartan would reduce cardiac 
morbidity and mortality more than amlodipine in hyperten-
sive patients at high cardiovascular risk.8 Amlodipine treat-
ment was associated with a more prompt and robust reduction 
in BP than valsartan treatment, particularly early in the trial. 
The primary composite end point of cardiac mortality and 
morbidity was reduced equally by both groups.8 However, 
amlodipine was associated with a statistically significant 16% 
reduction in the incidence of myocardial infarction and a 
near-significant reduction in stroke (Table 1). Subanalysis of 
VALUE results reported that valsartan monotherapy reduced 
the risk of heart failure and new onset diabetes to a greater 
extent compared to amlodipine monotherapy.37 These data 
are consistent with the findings in ALLHAT that amlodipine 
does not prevent heart failure as effectively as some other 
antihypertensive drugs.
Anglo-Scandinavian Cardiac Outcomes Trial – Blood 
Pressure Lowering Arm (ASCOT-BPLA)38 compared a “stan-
dard” antihypertensive regimen (β-blocker [atenolol] plus/
minus diuretic [thiazide]) with a more “contemporary” regi-
men (CCB [amlodipine] plus/minus ACE inhibitor [perindo-
pril]) on the combined primary outcome (nonfatal myocardial 
infarction and fatal coronary heart disease).39 ASCOT-BPLA 
was terminated early due to benefits in cardiovascular mortal-
ity and all-cause mortality in patients treated with amlodipine 
versus atenolol-based treatment. Results from the ASCOT 
Conduit Artery Function Evaluation (CAFE) 40 study assessed 
the effects of atenolol- versus amlodipine-based therapy on 
central arterial blood pressure and showed that central arterial 
blood pressure was more favorably influenced by the amlo-
dipine- than the atenolol-based regimen when compared with Vascular Health and Risk Management 2009:5 381
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peripheral BP. Central, arterial pulse pressure was observed 
to be a more important and an independent predictor of 
cardiovascular and renal outcomes.
Heart failure trials
The Prospective Randomized Amlodipine Survival Evaluation 
Study (PRAISE) trial41 evaluated the safety of amlodipine 
in patients with severe heart failure with an ejection 
fraction ,30%. Among patients with ischemic heart disease, 
there was no difference between the amlodipine and placebo 
groups in the occurrence of either death from any cause 
and hospitalization for major cardiovascular events. How-
ever, among patients with nonischemic cardiomyopathy, 
amlodipine reduced the combined risk of fatal and nonfatal 
events by 31% and decreased the risk of death by 46% and 
showed that it did not increase cardiovascular morbidity or 
mortality in patients with severe heart failure.41
Coronary artery disease trials
The other area of major randomized controlled trials 
of amlodipine have been in the cohort of patients with 
atherosclerosis. The Prospective Randomized Evaluation 
of the Vascular Effects of Norvasc Trial (PREVENT) was 
a multicenter, randomized, placebo-controlled, clinical 
trial designed to test whether amlodipine would slow the 
progression of early coronary atherosclerosis in patients 
with angiographically documented coronary artery 
disease.42 Although there was no difference in the coronary 
angiographic endpoint, there was a significant reduction 
in the progression of carotid atherosclerosis as well as a 
significant reduction in the risk of stroke.
Comparison of Amlodipine vs Enalapril to Limit 
Occurrences of Thrombosis (CAMELOT)43 study compared 
the incidence of cardiovascular events among patients with 
angiographically documented coronary artery disease and 
normal BP randomized to amlodipine, enalapril, or placebo.43 
After 24 months, there was a significant reduction in the 
incidence of cardiovascular events in the amlodipine arm com-
pared with placebo. Compared with baseline, intravascular 
ultrasound (IVUS) showed progression in the placebo group, 
a trend toward progression in the enalapril group (p = 0.08), 
but no progression in the amlodipine group (p = 0.31).
Atorvastatin
Atorvastatin, like other statins, has been shown to reduce 
LDL cholesterol and reduce the risk of cardiovascular 
morbidity and mortality (Table 2). In addition, statins have 
pleiotropic effects.
Coronary artery disease trials
The Pravastatin or Atorvastatin Evaluation and Infection 
Therapy – Thrombolysis in Myocardial Infarction (PROVE 
IT-TIMI 22) trial compared standard treatment (pravastatin 
40 mg daily) with more intensive treatment (atorvastatin 
80 mg daily) in patients who had been hospitalized for an 
acute coronary syndrome within the preceding 10 days.44 
The primary outcome was a composite of death from any 
cause, myocardial infarction, severe unstable angina, revas-
cularization or stroke. A 16% reduction in the hazard ratio 
favored atorvastatin. The findings from PROVE IT-TIMI 
22 have been confirmed by the results from the Treating to 
New Targets (TNT) Study.45
The TNT study examined the effectiveness of low-dose 
versus high-dose atorvastatin therapy on major cardiovas-
cular events. TNT demonstrated that the use of atorvastatin 
80 mg to reduce LDL-C to 77 mg/dL provided additional 
clinical benefits in stable coronary heart disease patients, 
compared with reduction of LDL-C to 100 mg/dL with 
atorvastatin 10 mg. The composite primary outcome – first 
occurrence of a major cardiovascular event – showed a 
relative risk reduction of 22%.46 TNT’s findings confirm 
the growing body of evidence that reducing LDL-C below 
current guideline-recommended levels confers significant 
clinical benefits.
The Incremental Decrease in Endpoints through 
Aggressive Lipid Lowering (IDEAL) study compared 
patients with a history of acute myocardial infarction treated 
with a high dose of atorvastatin (80 mg/day) with those 
receiving the standard dose of simvastatin (20 mg/day).47 
Mean LDL-C levels were 104 mg/dL in the simvastatin 
group and 81 mg/dL in the atorvastatin group during treat-
ment. The risk reduction between the treatment groups (11%) 
in the primary endpoint of major coronary events failed to 
reach significance (p = 0.07). However, significant reductions 
favoring the atorvastatin treatment group were observed for 
the occurrence of secondary cardiovascular endpoints such as 
coronary events and nonfatal acute myocardial infarction.
The Reversal of Atherosclerosis with Aggressive Lipid 
Lowering (REVERSAL) study used the same doses of 
atorvastatin and pravastatin as the PROVE IT study in 
patients with angiographically demonstrated CAD. The 
results of the REVERSAL study showed that atorvastatin 
80 mg halted plaque progression (as monitored by IVUS), 
while pravastatin did not.48
The Aggressive Lipid-Lowering Initiation Abates New 
Cardiac Events (ALLIANCE) trial compared a focused 
treatment strategy using atorvastatin with usual medical care. Vascular Health and Risk Management 2009:5 383
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Table 2 Key outcome studies of atorvastatin
Trial Study groups Population Total N All-cause mortality Myocardial infarction Stroke
ALLiANCe49 Atorvastatin 
(10–80 mg) vs 
Ongoing usual care
Coronary artery 
disease
2442 0.92 (0.72–1.18) 0.52 (0.38–0.74) 0.87 (0.55–1.38)
ASCOT-LLA5 Atorvastatin (10 mg) 
vs Placebo
Substudy of patients 
with hypertension, 
average or lower 
cholesterol, and at least 
three other risk factors
10305 0.87 (0.71–1.06) 0.65 (0.50–0.83) 0.73 (0.56–0.96)
CARDS7 Atorvastatin (10 mg) 
vs Placebo
Patients with diabetes 
without high LDL-C 
levels
2838 0.73 (0.53–1.01) 0.53 (0.35–0.81) 0.53 (0.31–0.90)
GReACe50 Atorvastatin 
(10–80 mg) vs usual 
care by GP
Heart failure 1600 0.58 (0.35–0.95) 0.46 (0.32–0.66) 0.53 (0.24–0.18)
PROVe iT44 Pravastatin (40 mg) 
vs atorvastatin 
(80 mg)
Acute coronary 
syndromes
4162 0.72 (0.5–1.02) 0.87 (0.7–1.1) 1.08 (0.4–1.6)
TNT46 Atorvastatin (10 mg) 
vs atorvastatin 
(80 mg)
Coronary artery 
disease
10001 1.01 (0.85–1.19) 0.78 (0.69–0.89) 0.75 (0.59–0.96)
iDeAL47  Atorvastatin (80 mg) 
vs simvastatin 20 mg
Coronary artery 
disease
8888  0.98 (0.85–1.13)  0.89 (0.78–1.01)  0.87 (0.7–1.08) 
Abbreviations: ALLiANCe, Aggressive Lipid-Lowering initiation Abates New Cardiac events;   ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm;   
CARDS, Collaborative Atorvastatin Diabetes Study; GReACe, Greek Atorvastatin and Coronary Heart Disease evaluation; iDeAL, incremental Decrease in Clinical endpoints 
Through Aggressive Lipid Lowering; PROVe iT, Pravastatin or Atorvastatin evaluation and infection Therapy trial; TNT, Treating to New Targets. 
The study showed that aggressive treatment with atorvastatin 
was associated with significantly lower LDL cholesterol 
levels over usual care accompanied by improved outcomes 
in the composite primary end point of cardiovascular events 
and particularly nonfatal myocardial infarction.49
The Greek Atorvastatin and Coronary-heart-disease 
Evaluation (GREACE) study assessed the effect of atorvastatin 
on mortality and morbidity in patients with coronary heart 
disease. The treatment regimen was atorvastatin, 10–80 mg/day, 
titrated to LDL-C , 100 mg/dL, or usual care. Total mortality 
was lower with atorvastatin than with usual care. Similar reduc-
tions with atorvastatin compared to usual care were seen in 
coronary mortality and coronary morbidity.50
Hypertension and diabetes trials
In the recent Collaborative Atorvastatin Diabetes Study 
(CARDS), atorvastatin 10 mg reduced the death rate 
among patients with type 2 diabetes mellitus and relatively 
low-cholesterol levels by 27% compared with placebo.7 The 
CARDS study was terminated after approximately two years 
early due to the highly significant reduction in cardiovascular 
events, including heart attack and stroke, in those patients 
receiving atorvastatin treatment.
The lipid-lowering arm of the ASCOT trial investigated, 
in a factorial design, the effects of simultaneous treatment 
with antihypertensive and lipid-lowering therapy (atorvastatin 
10 mg) among hypertensive patients with normal to mildly 
elevated lipid levels and at least three other cardiovascular 
risk factors.5 The lipid-lowering study arm was terminated 
nearly two years early due to the highly significant (36%) 
decrease in the cumulative incidence of nonfatal myocardial 
infarction and CHD mortality among patients receiving treat-
ment to lower both BP and lipids compared with patients 
receiving treatment for hypertension alone.
Key studies evaluating amlodipine  
and atorvastatin combination 
therapy
Clinical trials have been conducted (comparative and non 
comparative) to assess the efficacy and safety of the com-
bination therapy. Single-pill therapy in the Treatment of 
Concomitant Hypertension and Dyslipidemia (GEMINI),22 
GEMINI- Asia Pacific, Middle East, Africa, Latin America 
(GEMINI-ALAA),51 An international, multicenter, open label 
study to assess the effectiveness of amlodipine–atorvastatin Vascular Health and Risk Management 2009:5 384
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combination in subjects with hypertension and dyslipidemia in 
the UK and Canada (JEWEL I), JEWEL Europe (JEWEL II),52 
Clinical Utility of Caduet in Simultaneously Achieving Blood 
Pressure and Lipid End Points (CAPABLE)53 are noncom-
parative, titration-to-goal, multicenter studies, which showed 
the efficacy and effectiveness of the combination medica-
tion at achieving both LDL and BP goals. AVALON and 
RESPOND are two randomized double-blind, multicenter 
trials that compared the efficacy of the coadministration of 
amlodipine and atorvastatin with that of single-agent therapy 
or placebo over eight weeks.25,54 The Anglo-Scandinavian 
Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) 
is a randomized, double-blind, multicenter trial that compared 
the efficacy of amlodipine plus atorvastatin with that of 
placebo over 3.3 years.55
ASCOT-LLA study evaluated data from patients who had 
received atorvastatin 10 mg once daily or placebo in addition 
to their antihypertensive regimen as described previously.55 
In ASCOT-LLA, the relative risk of nonfatal myocardial 
infarction and fatal coronary heart disease was reduced by 
36% in the group receiving atorvastatin plus either antihyper-
tensive regimen compared with the group receiving placebo 
plus either antihypertensive regimen.5
In the multicenter Atorvastatin and Amlodipine in Patients 
with Elevated Lipids and Hypertension (AVALON)25 trial 
more patients receiving combination therapy achieved their 
BP goal than patients receiving atorvastatin, and more patients 
receiving combination therapy achieved their LDL-C goal 
than patients receiving amlodipine.25 Similarly, significantly 
more patients receiving combination therapy achieved both 
their BP and LDL-C goals compared with those receiving 
single-agent therapy.25 The mean Framingham estimated 
10-year CHD risk was significantly with combination therapy 
than with single-agent therapy.
In the Efficacy and Safety of Fixed-Dose Combinations 
of Amlodipine and Atorvastatin in the Treatment of 
Patients with Concomitant Hypertension and Dyslipidemia 
(RESPOND)54 study, hypertensive patients with dyslipidemia 
the concomitant use of amlodipine plus atorvastatin did 
not modify the efficacy achieved with either agent alone.54 
In an analysis of risk, the mean Framingham estimated 
10-year CHD risk was reduced from mean baseline values of 
15.8%–18.0% to endpoint values of 7.3%–10.7% in patients 
receiving combination therapy.54
Tolerability/safety data
In the double-blind phase of the AVALON trial, the rate 
of treatment discontinuation for any reason was similar in 
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groups receiving amlodipine 5 mg plus atorvastatin 10 mg 
(7.7%), amlodipine 5 mg alone (7.0%), or atorvastatin 
10 mg alone (7.5%), but slightly higher in the placebo group 
(9.6%). Adverse events reported most frequently in the 
combination therapy group compared with the placebo group 
during this phase were peripheral edema (5.3% vs 2.1%), 
myalgia (4.8% vs 2.1%), and sinusitis (2.9% vs 0.8%).25 
In RESPOND trial combination-treated patients did not 
experience any increase in treatment-related side effects 
compared with amlodipine or atorvastatin monotherapy. The 
most common treatment-related side effects were peripheral 
edema (9.4% vs 2.7%), headache and dizziness compared 
to placebo. These events were mild to moderate in severity. 
The incidence of treatment-related myalgia in combination-
treated patients was low (1.0%) and similar to that in patients 
treated with amlodipine alone (1.4%), atorvastatin alone 
(1.1%), or placebo (1.8%).54 GEMINI study showed that 
amlodipine/atorvastatin combination pill has a safety profile 
consistent with its components. These data demonstrated 
that co-administered amlodipine plus atorvastatin is well 
tolerated in patients with hypertension and additional risk 
factors, and that the adverse events observed are similar in 
nature, severity and frequency to those seen with amlodipine 
or atorvastatin administered alone.
Pharmacoeconomic considerations/
quality of life
Treatment with a single tablet of amlodipine/atorvastatin has 
been shown to be more cost effective than two-tablet therapy 
and may be slightly more effective when real world adherence 
levels are considered.56,57 It has been shown that the clinical 
and economic consequences of adding atorvastatin to an 
existing amlodipine-based antihypertensive regimen using 
a single-pill formulation versus a two-pill regimen among 
patients similar to the ASCOT–LLA population showed 
the single-pill formulation to be less costly and could be 
slightly more effective when real world adherence levels are 
considered.57
Conclusion
Concomitant hypertension and dyslipidemia are very 
common and are associated with a high risk of cardiovascular 
disease. Despite the widespread availability of safe and 
efficacious medications for the treatment of hypertension 
and dyslipidemia, the management of these conditions is far 
from optimal. Indeed, epidemiological studies have indicated 
that 90% of patients with concomitant hypertension and 
dyslipidemia fail to achieve their therapeutic targets for both 
conditions. Moreover, the optimal LDL goal in patients with 
risk factors has been steadily declining, necessitating the 
treatment of bigger population subsets.
Amlodipine and atorvastatin both have excellent efficacy 
and safety profiles for the treatment of hypertension and 
dyslipidemia, respectively. Clinical trials have shown that 
co-administration of these two agents, across the dose range, 
does not modify the efficacy of either medication. Moreover, the 
efficacy and safety of single-pill amlodipine/atorvastatin therapy 
has also been demonstrated in patients at different levels of risk 
for CVD. The association of amlodipine and atorvastatin in a 
single pill formulation with flexible dosing combinations offers 
the possibility of simplifying the process for treating hyperten-
sion and/or angina and dyslipidemia and thereby improving 
medication adherence.66 The concept of dual-therapy pill also 
highlights the importance of managing both the risk factors 
simultaneously, both for the practitioner and the patient and 
open the floodgates to development and release of other cross-
risk-factor, single-pill combinations, and a future polypill.
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